There are different kinds of adjuvants, but the ones that use squalene include a whole host of coronaviruses - like SARS-CoV, and MERS-CoV - so it makes sense that squalene would be used in a COVID-19 vaccine.
Sweden's Prime Minister Stefan Lofven pledged US$10 million while Canadian Prime Minister Justin Trudeau touted a Can$440 million (S$450 million) commitment made last week, half of which will go to low or middle-income countries.
This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August.
Serum Institute's new vaccine production facility in Pune - inaugurated in September previous year - will become the largest single-use bioreactor-based vaccine manufacturing line in the world. The data also supports further testing of the investigational vaccine candidate in older adults in an ongoing phase 3 trial.
VLP's RNA-based vaccine candidate was selected for funding by the Japan Agency for Medical Research and Development.
The institute has committed its own resources of around $300-400 million in operational expenditure for manufacturing the Covid-19 Covishield vaccine. It is gradually ramping up production and expects to manufacture 100 million doses by December.
Speaking at the FT's U.S. Pharma and Biotech Conference, Bancel said: "November 25 is the time we will have enough safety data to be able to put into a EUA [emergency use authorization] file that we would send to the FDA - assuming that the safety data is good; in other words, a vaccine is deemed to be safe".
The vaccine contains synthetic peptide antigens or fragments of the virus. "This collaboration brings us another step closer to achieving this goal", Berkley said.
This alliance would provide upfront capital to SII to help increase manufacturing capacity so that once a vaccine or vaccines, gains necessary regulatory approvals, doses can be distributed at scale to low and middle-income countries as part of the Gavi COVAX AMC mechanism. AstraZeneca's vaccine, if successful, will be available to 61 Gavi-eligible countries.
Both AstraZeneca and Novavax's candidates would be available for procurement once World Health Organization prequalification and full license if received.
- NFL Postpones Titans/Steelers To Monday Or Tuesday
- Prime Minister reaches deal with opposition NDP to avert an election
- Messi scores since failed exit as Barcelona thumps Villarreal for 4-0
- Toronto Public Health calls social bubble ineffective as COVID-19 cases spike
- Huge Lead Emerges in Mail Voting
- Year-old dies from brain-eating amoeba
- The Rock Publicly Endorses Joe Biden For President
- Hundreds detained during 50th day of protests in Belarus
- NASA to Send $ 23 Million Space Toilet to ISS
- Stamkos out for remainder of Stanley Cup Final